AJJ Medtech Holdings (SGX:584) Beta: 2.5530 (As of Jul. 01, 2026)


What is AJJ Medtech Holdings Beta?

AJJ Medtech Holdings SGX:584 -20.00% Beta is 2.5530 as of Jul. 01, 2026. The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-01), AJJ Medtech Holdings's Beta is 2.5530.


AJJ Medtech Holdings  (SGX:584) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


AJJ Medtech Holdings Beta Related Terms


AJJ Medtech Holdings Beta Historical Data

* Premium members only.

The historical data trend for AJJ Medtech Holdings's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AJJ Medtech Holdings Beta Chart

AJJ Medtech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.18 2.12 1.76 2.98

AJJ Medtech Holdings Quarterly Data
Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 1.77 2.13 2.98 2.55

SGX:584 vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, AJJ Medtech Holdings's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AJJ Medtech Holdings Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AJJ Medtech Holdings's Beta distribution charts can be found below:

* The bar in red indicates where AJJ Medtech Holdings's Beta falls into.



AJJ Medtech Holdings Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.5530 mean?
AJJ Medtech Holdings (SGX:584) has a Beta of 2.5530 as of Jul. 01, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for AJJ Medtech Holdings and its competitors.
Is AJJ Medtech Holdings' Beta too high?
AJJ Medtech Holdings' current Beta is 2.5530.
How does AJJ Medtech Holdings' Beta compare to ABT and SYK?
AJJ Medtech Holdings' Beta of 2.5530 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for AJJ Medtech Holdings and its competitors. AJJ Medtech Holdings's current Beta is 2.5530. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AJJ Medtech Holdings stock overvalued right now?
Based on GuruFocus' analysis, AJJ Medtech Holdings (SGX:584) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.01, compared to a current price of S$0.00 — trading 60% below its estimated fair value. The current Beta is 2.5530. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For AJJ Medtech Holdings (SGX:584), the current Beta is 2.5530 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AJJ Medtech Holdings Business Description

Address 8 Commonwealth Lane, No. 02-04, Grande Building, Singapore, SGP, 149555
AJJ Medtech Holdings Ltd is a healthcare technology company building an integrated platform across medical devices, digital systems, and intelligent care infrastructure in Singapore, Southeast Asia, and selected international markets. It integrates artificial intelligence, robotics, and healthcare systems to support healthcare delivery across the patient care continuum. Its portfolio includes diagnostic systems, medical and dental devices, consumables, digital and robotics-enabled healthcare solutions, and turn-key supply-chain solutions. Its segments are corporate and investment holding, healthcare products and services, and healthcare digital products, which generate maximum revenue. It operates mainly in Singapore, and its revenue is derived from the sale of medical healthcare products.